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Abstract
Background: Hepatic and pancreatic surgery is rarely performed in patients with end-stage renal
disease (ESRD). The present authors used a national clinical database to characterize outcomes and
perioperative risk in ESRD patients who require hepatic or pancreatic resection.
Methods: The 2005–2011 National Surgical Quality Improvement Program database was queried for all
patients undergoing hepatic or pancreatic resection. Patients were classified by the presence or absence
of ESRD. The independent effects of ESRD on outcomes were assessed after propensity score adjust-
ment and multivariable logistic regression.
Results: Of the 27 376 patients submitted to hepatic or pancreatic procedures identified in the data-
base, 101 patients were found to have preoperative ESRD. Patients with ESRD experienced perioperative
mortality at a rate similar to that in those without ESRD (5.0% versus 2.3%; P = 0.08). After risk
adjustment, the presence of ESRD was associated with three-fold higher odds of postoperative sepsis
(adjusted odds ratio: 2.98, P = 0.014), but no significant differences in mortality or major complication
rates.
Conclusions: Hepatic and pancreatic resections can be performed safely in selected patients with
ESRD. These patients may have an increased risk for the development of postoperative sepsis. Further
study is needed to characterize modifiable risk factors that impact outcomes in patients with ESRD who
require hepatic or pancreatic resection.
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Introduction
Hepatic and pancreatic surgery is rarely performed in patients
with end-stage renal disease (ESRD), in part as a result of percep-
tions of prohibitive operative risk. Although the safety of hepatic
and pancreatic resections has improved significantly in the
modern era, these complex abdominal procedures are still associ-
ated with significant perioperative morbidity even in healthy
patients. Patients with ESRD are at increased risk for cardiovas-
cular complications and exhibit abnormalities in immunologic
function and coagulation, which have significant implications on
their ability to tolerate and recover from major abdominal
surgery.1,2 These considerations are likely to contribute to reluc-
tance on the part of surgeons to recommend major abdominal
surgery to these patients.
However, the ESRD population in the USA continues to grow.
There are currently an estimated 500 000 patients with ESRD on
dialysis and this number is projected to grow by 7% per year.3 As
the life expectancy of patients with ESRD improves, it is likely that
more patients will present with hepatic and pancreatic pathologies
requiring operative intervention.
In view of the relative paucity of studies examining the out-
comes of complex abdominal surgery in ESRD patients, the
present authors sought to explore this topic specifically in relation
to hepatic and pancreatic resection. The primary goals of this
study were to characterize perioperative outcomes of hepatic or
pancreatic resection in patients with ESRD and to compare these
outcomes with those in patients without ESRD. As patients in this
population frequently have numerous other comorbidities, risk
adjustment using propensity-based techniques was performed.
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Materials and methods
The 2005–2011 American College of Surgeons National Surgical
Quality Improvement Program (ACS-NSQIP) Participant User
Files (PUFs) were queried for all patients undergoing hepatic or
pancreatic resection. Patients were included for analysis using
Current Procedural Terminology (CPT) codes for partial hepa-
tectomy (47120, 47122, 47125 and 47130), distal pancreatectomy
(48140, 48145, 48146) and pancreaticoduodenectomy (Whipple-
type procedure: 48150, 48152–48154). Patients coded as submit-
ted to an emergent operation and patients with American
Society of Anesthesiologists (ASA) class 5 status, defined as
moribund and not expected to survive without the operation,
were excluded from analysis. The main predictor variable of
interest was the presence of ESRD, defined as requiring treat-
ment with peritoneal dialysis, haemodialysis, haemofiltration,
haemodiafiltration or ultrafiltration within the 2 weeks prior to
surgery. The primary outcome measure was rate of major com-
plications, defined a priori as the occurrence of one or more of
the available major complications captured by NSQIP, which
roughly correspond to complications of Clavien–Dindo Grade
III or higher.
Statistical analysis
For continuous and categorical variables, measures of central
tendency and proportions were assessed, respectively. Preopera-
tive baseline patient characteristics and specific postoperative
complications and endpoints were included in univariate com-
parisons of patients with and without ESRD, using Pearson’s
chi-squared test for categorical variables and Student’s t-test for
continuous variables. Because of the significant differences in
baseline characteristics between patients with and without
ESRD, patients were matched according to their propensity for
undergoing an operation in the setting of ESRD, using a
3:1 optimized nearest-neighbour algorithm.4–6 To adjust for
residual imbalance following matching, a non-parsimonious
multivariable logistic regression model was then created in order
to estimate the independent effect of ESRD on the study’s
primary and secondary endpoints. As a post hoc sensitivity
analysis focusing on patients submitted to the highest-risk pro-
cedures, two subsets of the original study population were then
examined separately: (i) patients submitted to major hepatec-
tomy (defined as trisegmentectomy or right hepatectomy), and
(ii) patients submitted to pancreaticoduodenectomy.
Model diagnostics and balance were assessed; no major model
assumptions were violated. In a manner consistent with previous
studies using ACS-NSQIP data, laboratory values were catego-
rized as normal or abnormal using standard cut-offs, and missing
laboratory data were assigned a third categorical indicator
variable.7–9 Missing data for other variables were handled with
case-wise deletion, given the substantial completeness of NSQIP
data. A P-value of ≤0.05 was used to indicate statistical signifi-
cance for all comparisons and analyses of outcomes. Statistical
analyses were performed using R Version 3.0.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
A total of 27 376 patients were identified in the ACS-NSQIP data-
base as meeting the study inclusion criteria. Of these, 10 175
(37.2%) underwent partial hepatectomy, 5608 (20.5%) under-
went distal pancreatectomy and 11 593 (42.3%) underwent
pancreatoduodenectomy. A total of 101 patients were identified as
having preoperative ESRD (Fig. 1). Baseline characteristics in all
patients stratified by ESRD status are shown in Table 1. Compared
with the non-ESRD controls, patients with ESRD were more often
male (60.4% versus 48.4%; P = 0.021), had higher ASA scores
(P < 0.001), more often met criteria for systemic inflammatory
response syndrome preoperatively (5.9% versus 1.5%; P < 0.001),
more often had non-independent functional status (13.9% versus
2.0%; P < 0.001), and had lower median haematocrit (35.5%
versus 38.8%; P < 0.001). After propensity matching, groups were
highly similar without significant differences (Table 2).
In an unadjusted comparison referring to the study’s primary
outcomes, patients with ESRD did not show increased
perioperative mortality (5.0% versus 2.3%; P = 0.08), but did have
a significantly higher rate of major complications (45.5% versus
28.5%; P < 0.001) (Table 3). Similarly, patients with ESRD had a
higher rate of overall complications (48.5% versus 35.9%;
P = 0.011), a longer median length of stay (10 days versus 7 days;
P < 0.001), and a higher rate of postoperative sepsis (19.8%
versus 8.4%; P < 0.001). Following propensity matching and
multivariable logistic regression, ESRD was not found to be
NSQIP PUFs HPB procedures
n = 27 731
Non-elective operations
n = 355
Liver resection
n = 10 175
ESRD
n = 38
ESRD
n = 25
ESRD
n = 38
Distal
pancreatectomy
n = 5608
Whipple procedure
n = 11 593
Figure 1 Study design showing patient selection. NSQIP, National
Surgical Quality Improvement Program; PUFs, Participant User
Files; HPB, hepatopancreatobiliary; ESRD, end-stage renal disease
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associated with increased odds of major complications [adjusted
odds ratio (AOR) 0.98, P = 0.95]. Patients with ESRD, however,
had nearly three-fold higher odds of sepsis compared with their
non-ESRD counterparts (AOR 2.98, P = 0.014). There were no
statistically significant differences in other secondary outcomes,
including mortality (AOR 0.97, P = 0.96), reoperation (AOR 1.17,
P = 0.75), respiratory complications (AOR 1.77, P = 0.14) and
surgical site infection (AOR 0.94, P = 0.89) (Table 4).
In a sensitivity analysis of the subgroup of patients undergoing
pancreaticoduodenectomy (Fig. 2), ESRD was found to impose
two-fold higher odds for the occurrence of a major complication
(AOR 2.35, P = 0.025), as well as for a respiratory complication
Table 1 Baseline characteristics of patients submitted to major hepatopancreatobiliary procedures, stratified by end-stage renal disease
(ESRD) status
Variable All patients
(n = 27 376)
Patients without ESRD
(n = 27 275)
Patients with ESRD
(n = 101)
P-value
Age, years, median (range) 62 (53–71) 62 (53–71) 60 (53–68) 0.192
Female sex, n (%) 14 091 (51.5%) 14 051 (51.6%) 40 (39.6%) 0.021
ASA classification <0.001
1 (no disturbance) 377 (1.4%) 377 (1.4%) 0
2 (mild disturbance) 8616 (31.5%) 8615 (31.6%) 1 (1.0%)
3 (severe disturbance) 17 137 (62.6%) 17 078 (62.6%) 59 (58.4%)
4 (life-threatening) 1246 (4.6%) 1205 (4.4%) 41 (40.6%)
5 (moribund) 0 0 0
Procedure type, n (%) 0.487
Distal pancreatectomy 5608 (20.5%) 5583 (20.5%) 25 (24.8%)
Liver resection 10 175 (37.2%) 10 137 (37.2%) 38 (37.6%)
Whipple procedure 11 593 (42.3%) 11 555 (42.4%) 38 (37.6%)
Preoperative sepsis, n (%) <0.001
None 26 600 (97.9%) 26 509 (97.2%) 91 (90.1%)
SIRS 425 (1.6%) 419 (1.5%) 6 (5.9%)
Sepsis 121 (0.4%) 119 (0.4%) 2 (2.0%)
Septic shock, 12 (0.0004%) 10 (0.0004%) 2 (2.0%)
Dyspnoea, n (%) 2349 (8.6%) 2332 (8.5%) 17 (16.8%) 0.005
Non-independent functional status, n (%) 563 (2.1%) 549 (2.0%) 14 (13.9%) <0.001
DNR status 46 (0.2%) 45 (0.2%) 1 (1.0%) 0.157
Tobacco use, n (%) 5354 (19.6%) 5333 (19.6%) 21 (20.8%) 0.851
Alcohol use, n (%) 686 (2.9%) 686 (2.9%) 0 0.187
Diabetes, n (%) 5479 (20.0%) 5431 (19.9%) 48 (47.5%) <0.001
COPD, n (%) 1075 (3.9%) 1069 (3.9%) 6 (5.9%) 0.431
CAD, n (%) 2221 (9.3%) 2204 (9.2%) 17 (19.1%) 0.003
Bleeding disorder, n (%) 806 (2.9%) 800 (2.9%) 6 (5.9%) 0.136
Recent steroid use, n (%) 540 (2.0%) 535 (2.0%) 5 (5.0%) 0.050
Disseminated malignancy, n (%) 4494 (16.4%) 4481 (16.4%) 13 (12.9%) 0.407
Recent weight loss, n (%) 3138 (11.5%) 3124 (11.5%) 14 (13.9%) 0.547
Recent chemotherapy (30 days), n (%) 1104 (4.6%) 1104 (4.6%) 0 0.036
Contaminated/dirty case, n (%) 2325 (8.5%) 2319 (8.5%) 6 (5.9%) 0.457
Bilirubin > 4 mg/dl, n (%) 1671 (6.9%) 1665 (6.9%) 6 (6.5%) 0.999
Haematocrit, %, median (range) 38.8 (35.4–41.7) 38.8 (35.4–41.7) 35.5 (31.1–39.3) <0.001
Albumin, g/dl, median (range) 3.9 (3.5–4.3) 3.9 (3.5–4.3) 3.4 (2.7–3.9) <0.001
WBC count, × 103/μl, median (range) 6.8 (5.5–8.4) 6.8 (5.5–8.4) 7.4 (5.6–9.1) 0.038
Platelets, × 103/μl, median (range) 241 (192–302) 241 (192–302) 213 (173–264) 0.086
ASA, American Society of Anesthesiologists; SIRS, systemic inflammatory response syndrome; DNR, do not resuscitate; COPD, chronic obstructive
pulmonary disease; CAD, coronary artery disease; WBC, white blood cell.
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(AOR 2.78, P = 0.011) and sepsis (AOR 2.55, P = 0.018). In the
subgroup of patients submitted to right hepatectomy or
trisegmentectomy, ESRD imposed no significantly increased odds
for any primary or secondary endpoints after adjustment
(Fig. 3).
Discussion
Very few patients with ESRD undergo complex abdominal
surgery, particularly hepatic or pancreatic resection. The reasons
for this are likely to be multifactorial, but a major factor is the
Table 2 Baseline characteristics of patients submitted to major hepatopancreatobiliary procedures, stratified by end-stage renal disease
(ESRD) status following 3:1 propensity matching
Variable Patients without ESRD
(n = 303)
Patients with ESRD
(n = 101)
P-value
Age, years, median (range) 60 (50.5–71) 60 (53–68) 0.790
Female sex, n (%) 124 (40.9%) 40 (39.6%) 0.907
ASA classification, n (%) 0.428
1 (no disturbance) 0 0
2 (mild disturbance) 11 (3.6%) 1 (1.0%)
3 (severe disturbance) 164 (54.1%) 59 (58.4%)
4 (life-threatening) 128 (42.2%) 41 (40.6%)
5 (moribund) 0 0
Procedure type, n (%) 0.322
Distal pancreatectomy 64 (21.1%) 25 (24.8%)
Liver resection 99 (32.7%) 38 (37.6%)
Whipple procedure 140 (46.2%) 38 (37.6%)
Preoperative sepsis, n (%) 0.114
None 284 (93.7%) 91 (90.1%)
SIRS 14 (4.6%) 6 (5.9%)
Sepsis 5 (1.7%) 2 (2.0%)
Septic shock 0 2 (2.0%)
Dyspnoea, n (%) 40 (13.2%) 17 (16.8%) 0.458
Non-independent functional status, n (%) 37 (12.2%) 14 (13.9%) 0.795
DNR status, n (%) 7 (3.7%) 1 (1.1%) 0.443
Tobacco use, n (%) 55 (18.2%) 21 (20.8%) 0.659
Alcohol use, n (%) 1 (0.5%) 0 0.999
Diabetes, n (%) 139 (45.9%) 48 (47.5%) 0.863
COPD, n (%) 17 (5.6%) 6 (5.9%) 0.999
CAD, n (%) 26 (15.5%) 17 (19.1%) 0.572
Bleeding disorder, n (%) 24 (7.9%) 6 (5.9%) 0.661
Recent steroid use, n (%) 12 (4.0%) 5 (5.0%) 0.775
Disseminated malignancy, n (%) 44 (14.5%) 13 (12.9%) 0.804
Recent weight loss, n (%) 37 (12.2%) 14 (13.9%) 0.795
Recent chemotherapy (30 days), n (%) 18 (10.7%) 0 <0.001
Contaminated/dirty case, n (%) 24 (7.9%) 6 (5.9%) 0.661
Bilirubin >4 mg/dl, n (%) 33 (11.9%) 6 (6.5%) 0.197
Haematocrit, %, median (range) 35.4 (31.9–39.8) 35.5 (31.1–39.3) 0.300
Albumin, g/dl, median (range) 3.5 (2.9–4.0) 3.4 (2.7–3.9) 0.184
WBC count, × 103/μl, median (range) 7 (5.4–8.868) 7.4 (5.6–9.1) 0.568
Platelets, × 103/μl, median (range) 230.5 (173.2–292.0) 213.0 (173.0–264.0) 0.285
ASA, American Society of Anesthesiologists; SIRS, systemic inflammatory response syndrome; DNR, do not resuscitate; COPD, chronic obstructive
pulmonary disease; CAD, coronary artery disease; WBC, white blood cell.
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Table 3 Unadjusted outcomes in patients submitted to major hepatopancreatobiliary procedures stratified by end-stage renal disease
(ESRD) status
Variable All patients
(n = 27 376)
Patients without ESRD
(n = 27 275)
Patients with ESRD
(n = 101)
P-value
Mortality within 30 days, n (%) 621 (2.3%) 616 (2.3%) 5 (5.0%) 0.080
Overall complication rate, n (%) 9840 (35.9%) 9791 (35.9%) 49 (48.5%) 0.011
Major complication rate, n (%) 7816 (28.6%) 7770 (28.5%) 46 (45.5%) <0.001
Early return to operating room, n (%) 1446 (5.3%) 1436 (5.3%) 10 (9.9%) 0.063
Length of stay, days, median (range) 7 (6–12) 7 (6–12) 10 (6–20.5) <0.001
Operative time, min, median (range) 277 (191–378) 277 (191–378) 269 (190–355) 0.426
Superficial surgical site infection, n (%) 1906 (7.0%) 1901 (7.0%) 5 (5.0%) 0.557
Deep surgical site infection, n (%) 435 (1.6%) 433 (1.6%) 2 (2.0%) 0.676
Organ space surgical site infection, n (%) 2390 (8.7%) 2379 (8.7%) 11 (10.9%) 0.552
Wound dehiscence, n (%) 333 (1.2%) 332 (1.2%) 1 (1.0%) 0.999
Sepsis, n (%) 2298 (8.4%) 2278 (8.4%) 20 (19.8%) <0.001
Septic shock, n (%) 898 (3.3%) 896 (3.3%) 2 (2.0%) 0.776
Pneumonia, n (%) 1156 (4.2%) 1152 (4.2%) 4 (4.0%) 0.999
Re-intubation, n (%) 1092 (4.0%) 1081 (4.0%) 11 (10.9%) 0.001
Prolonged (> 48 h) vent dependence, n (%) 1195 (4.4%) 1174 (4.3%) 21 (20.8%) <0.001
Pulmonary embolism, n (%) 317 (1.2%) 317 (1.2%) 0 0.635
Acute kidney injury, n (%) 237 (0.9%) 237 (0.9%) 0 0.999
Urinary tract infection, n (%) 1223 (4.5%) 1219 (4.5%) 4 (4.0%) 0.999
Stroke, n (%) 90 (0.3%) 89 (0.3%) 1 (1.0%) 0.283
Coma, n (%) 44 (0.2%) 41 (0.2%) 3 (3.0%) 0.001
Cardiac arrest, n (%) 281 (1.0%) 277 (1.0%) 4 (4.0%) 0.020
Myocardial infarction, n (%) 152 (0.6%) 150 (0.5%) 2 (2.0%) 0.109
Postoperative bleeding, n (%) 3028 (11.1%) 3008 (11.0%) 20 (19.8%) 0.008
Deep venous thrombosis, n (%) 577 (2.1%) 573 (2.1%) 4 (4.0%) 0.165
Table 4 Adjusted odds of outcomes in patients submitted to major
hepatopancreatobiliary procedures stratified by end-stage renal
disease (ESRD) after propensity matching and multivariable logistic
regression
Complication Odds ratio (95% CI) P-value
Mortality within 30 days 0.97 (0.26–3.6) 0.959
Early return to the OR 1.17 (0.43–3.19) 0.753
Major complication 0.98 (0.53–1.81) 0.949
Any complication 0.97 (0.52–1.79) 0.914
Respiratory complicationa 1.77 (0.83–3.78) 0.142
Surgical site infection 0.94 (0.43–2.09) 0.887
Sepsis or septic shock 2.98 (1.25–7.14) 0.014
aRespiratory complications defined as one or more of the following post-
operative complications: pneumonia; re-intubation, and prolonged
(>48 h) ventilation.
95% CI, 95% confidence interval; OR, operating room.
Early return to the OR
Major complication
Any complication
Respiratory complication
Surgical site infection
Sepsis or septic shock
Mortality (30-day) 0.962
P-value
0.474
0.025
0.067
0.011
0.414
0.018
0.0 1.0 2.0
Adjusted odds ratio
3.0
Figure 2 Adjusted odds for the occurrence of complications in the
subgroup of patients with end-stage renal disease submitted to
pancreaticoduodenectomy (Whipple technique). OR, operating
room
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common perception that procedures of this magnitude carry a
prohibitively high risk in ESRD patients.
A few recent studies have examined the effects of ESRD in a
wide spectrum of elective general and vascular surgical pro-
cedures using large national clinical databases.3,10,11 These studies
have demonstrated significantly increased risks for perioperative
mortality and morbidity in the ESRD population. Gajdos et al.
included hepatic and pancreatic procedures in an analysis among
several other general surgery operations, but did not characterize
specific outcomes in this population.3
Several factors may contribute to the increased operative risk
observed in this population. Patients with ESRD frequently have
other significant comorbidities, including cardiovascular disease
and diabetes, which make them susceptible to cardiovascular
complications such as myocardial infarction and stroke in the
perioperative period.Moreover, these patients commonly demon-
strate coagulation abnormalities related to uraemic platelet dys-
function and are thus susceptible to bleeding complications.2,12 In
addition, patients with ESRD have impaired immune function,
characterized by the induction of a proinflammatory state, dimin-
ished number and function of lymphoid cells, and phagocyte
dysfunction.1,13,14 This has significant implications for the devel-
opment of surgical site infection and sepsis. Finally, ESRD patients
are also at increased risk for pulmonary complications, possibly
related to hypoxaemia and hypocapnia induced by heart disease,
contributing to atelectasis and pneumonia.3 Beyond these signifi-
cant concerns, there are additional considerations in complex
hepatic or pancreatic resection. These procedures are character-
ized by large fluid shifts both intraoperatively and in the early
postoperative period. Patients with ESRD are less able to accom-
modate such large fluid shifts, which can potentially lead to com-
plications related to fluid overload.
In light of these numerous risk factors, the primary focus of the
present study was to characterize perioperative outcomes
in patients with ESRD submitted to complex hepatopan-
creaticobiliary procedures. Most of the previous literature on this
topic consists of relatively small single-institution series, which
have generally demonstrated the feasibility of performing safe
hepatic or pancreatic resection in highly selected patients with
renal dysfunction and ESRD.15–25 More recently, Squires and col-
leagues examined the effects of preoperative renal insufficiency on
outcomes in a large series of patients undergoing pancreatic resec-
tion.26 In this study, renal insufficiency was not associated with
increased postoperative mortality, but was an independent pre-
dictor of postoperative complications and respiratory failure by
multivariate analysis.26
The findings of the present study support the suggestion that
hepatic and pancreatic resections are not prohibitively high risk in
selected patients with ESRD, but are frequently associated with a
more difficult postoperative course. Similar rates of perioperative
mortality were observed in ESRD patients and non-ESRD
patients, but the former group showed a significantly increased
complication rate. After propensity matching to isolate the inde-
pendent effect of ESRD, followed by multivariate analysis, the
present analysis failed to find significantly increased odds of mor-
tality, major complications or reoperation in ESRD patients. Of
note, the analysis did find that ESRD patients had a three-fold
increased risk for the development of sepsis, which is consistent
with findings highlighted by Gajdos et al.3 and Drolet et al.,10 and
perhaps reflects the abnormalities of immune function in this
population.
In a specific examination of the subset of patients with ESRD
submitted to pancreaticoduodenectomy, significantly increased
odds for the occurrence of major complications, respiratory com-
plications and sepsis in the postoperative period emerged. This
may reflect the reduced capacity of ESRD patients to tolerate these
lengthy, complex operations with their associated physiologic
stress and significant potential for the occurrence of septic com-
plications in the postoperative period. Interestingly, no such trend
emerged among patients submitted to major liver resection and
an adjusted analysis of this group showed no increased risk for any
of the study parameters. These findings should be interpreted with
caution because the numbers of patients in each of these subsets
are limited, but they do give some indication that patients with
ESRD who undergo pancreaticoduodenectomy are likely to
experience a more difficult postoperative course with greater
potential for septic complications.
There are some important limitations of this study to consider.
Firstly, it is a retrospective study and is thus subject to the inherent
limitations of this type of analysis. Secondly, the patients in this
study with ESRD who underwent hepatic or pancreatic resection
represent a highly selected group of patients. However, it was not
possible to ascertain the specific selection criteria employed by
surgical teams in their decisions to proceed with surgery. It is
possible that this population of ESRD patients was healthier than
Early return to the OR
Major complication
Any complication
Respiratory complication
Surgical site infection
Sepsis or septic shock
Mortality (30-day) 0.990
P-value
0.703
0.625
0.912
0.891
0.819
0.980
0.0 1.0 2.0
Adjusted odds ratio
3.0
Figure 3 Adjusted odds for the occurrence of complications in the
subgroup of patients with end-stage renal disease submitted to
major hepatectomy (right hepatectomy or trisegmentectomy). OR,
operating room
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patients in previous studies as a result of the careful preoperative
evaluation performed prior to hepatic or pancreatic resection.
Thirdly, there are limitations in the data available for analysis in
the NSQIP database. Specifically, it was not possible to ascertain
the duration of renal failure (acute versus chronic) and the mode
of dialysis (peritoneal versus haemodialysis) in patients with
ESRD.
Conclusions
Hepatic and pancreatic resections can be safely performed in
selected patients with ESRD and these patients should not be
categorically excluded from consideration for these complex pro-
cedures. It is important to clearly outline and describe the increase
in complications these patients might expect when counselling
patients and family in the preoperative setting. Further research is
necessary to investigate which patients with ESRD best tolerate
hepatic or pancreatic resection, and to identify risk factors that
can be modified in order to optimize outcomes.
Conflicts of interest
None declared.
References
1. Betjes MG. (2013) Immune cell dysfunction and inflammation in end-
stage renal disease. Nat Rev Nephrol 9:255–265.
2. Jalal DI, Chonchol M, Targher G. (2010) Disorders of haemostasis asso-
ciated with chronic kidney disease. Semin Thromb Hemost 36:34–40.
3. Gajdos C, Hawn MT, Kile D, Robinson TN, Henderson WG. (2013) Risk of
major nonemergent inpatient general surgical procedures in patients on
long-term dialysis. JAMA Surg 148:137–143.
4. Arbogast P, Seeger JD, DEcIDE Methods Center Summary Variable
Working Group. Summary variables in observational research: propensity
scores and disease risk scores. Effective Health Care Program Research
Report No 33. (2012) Available at http://effectivehealthcare.ahrq.gov/
reports/final.cfm (last accessed September 2013).
5. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer
T. (2006) Variable selection for propensity score models. Am J Epidemiol
163:1149–1156.
6. Pearl J. (2009) Causal inference in statistics: an overview. Stat Surv
3:96–146.
7. Khuri SF, Daley J, Henderson W, Hur K, Gibbs JO, Barbour G et al. (1997)
Risk adjustment of the postoperative mortality rate for the comparative
assessment of the quality of surgical care: results of the National Veterans
Affairs Surgical Risk Study. J Am Coll Surg 185:315–327.
8. Cohen ME, Dimick JB, Bilimoria KY, Ko CY, Richards K, Hall BL. (2009)
Risk adjustment in the American College of Surgeons National Surgical
Quality Improvement Program: a comparison of logistic versus hierarchi-
cal modelling. J Am Coll Surg 209:687–693.
9. Dimick JB, Osborne NH, Hall BL, Ko CY, Birkmeyer JD. (2010) Risk
adjustment for comparing hospital quality with surgery: how many
variables are needed? J Am Coll Surg 210:503–508.
10. Drolet S, Maclean AR, Myers RP, Shaheen AA, Dixon E, Donald Buie W.
(2010) Morbidity and mortality following colorectal surgery in patients
with end-stage renal failure: a population-based study. Dis Colon Rectum
53:1508–1516.
11. Gajdos C, Hawn MT, Kile D, Henderson WG, Robinson T, McCarter M
et al. (2013) The risk of major elective vascular surgical procedures in
patients with end-stage renal disease. Ann Surg 257:766–773.
12. Lutz J, Menke J, Sollinger D, Schinzel H, Thurmel K. (2014) Haemostasis
in chronic kidney disease. Nephrol Dial Transplant 29:29–40.
13. Kurts C, Panzer U, Anders HJ, Rees AJ. (2013) The immune system and
kidney disease: basic concepts and clinical implications. Nat Rev
Immunol 13:738–753.
14. Vaziri ND, Pahl MV, Crum A, Norris K. (2012) Effect of uraemia
on structure and function of immune system. J Ren Nutr 22:149–
156.
15. Nishizaki T, Kanematsu T, Matsumata T, Yasunaga C, Takenaka K,
Onoyama K et al. (1989) Maintenance haemodialysis poses few limita-
tions for liver surgery. Int Surg 74:101–103.
16. Yeh CN, Lee WC, Chen MF. (2005) Hepatic resection for hepatocellular
carcinoma in end-stage renal disease patients: two decades of experi-
ence at Chang Gung Memorial Hospital.World J Gastroenterol 11:2067–
2071.
17. Cheng SB, Wu CC, Shu KH, Ho WL, Chen JT, Yeh DC et al. (2001) Liver
resection for hepatocellular carcinoma in patients with end-stage renal
failure. J Surg Oncol 78:241–246; discussion 246–247.
18. Cheng SB, Yeh DC, Shu KH, Wu CC, Wen MC, Liu TJ et al. (2006) Liver
resection for hepatocellular carcinoma in patients who have undergone
prior renal transplantation. J Surg Oncol 93:273–278.
19. Kaibori M, Matsui Y, Kwon AH, Tokoro T, Kamiyama Y. (2005) Prognosis
of hepatocellular carcinoma after hepatectomy in patients with renal
dysfunction. World J Surg 29:375–381.
20. Lui SL, Yip PS, LamMF, Lo WK. (2003) Feasibility of reinstitution of CAPD
after partial hepatectomy in patients with malignant hepatic tumours.
Perit Dial Int 23:504–506.
21. Orii T, Takayama T, Haga I, Fukumori T, Amada N. (2008) Efficacy of a
liver resection for hepatocellular carcinoma in patients with chronic renal
failure. Surg Today 38:329–334.
22. Toshima T, Shirabe K, Yoshiya S, Muto J, Ikegami T, Yoshizumi T et al.
(2012) Outcome of hepatectomy for hepatocellular carcinoma in patients
with renal dysfunction. HPB 14:317–324.
23. Uchida H, Shibata K, Kai S, Iwaki K, Ohta M, Kitano S. (2008) Pylorus-
preserving pancreaticoduodenectomy in patients undergoing chronic
haemodialysis. Surg Today 38:1152–1154.
24. Yamagata M, Kanematsu T, Matsumata T, Nishizaki T, Utsunomiya T,
Sugimachi K et al. (1993) Possibility of hepatic resection in patients on
maintenance haemodialysis. Hepatogastroenterology 40:249–252.
25. Yasuda K, Tahara K, Kume M, Tsutsui S, Higashi H, Kitano S. (2007) Risk
factors for morbidity and mortality following abdominal surgery in
patients on maintenance haemodialysis. Hepatogastroenterology
54:2282–2284.
26. Squires MH 3rd, Mehta VV, Fisher SB, Lad NL, Kooby DA, Sarmiento JM
et al. (2014) Effect of preoperative renal insufficiency on postoperative
outcomes after pancreatic resection: a single institution experience of
1061 consecutive patients. J Am Coll Surg 218:92–101.
1022 HPB
HPB 2014, 16, 1016–1022 © 2014 International Hepato-Pancreato-Biliary Association
